This product is part of Glicix Labs’ ongoing research initiative focused on advanced GLP-1 multi-agonist compounds. Supplied in controlled batches, the formulation is intended for laboratory evaluation of chemical stability, pharmacodynamic behavior, and injection system performance. Not approved for human or veterinary use.
Published studies have investigated GLP-1 multi-agonist compounds under controlled conditions.
Alluvi supplies Retatrutide pens exclusively for laboratory research and development.
Not for human or veterinary consumption.
All figures are derived from third-party published studies and are shown only for academic context. All Alluvi products are supplied strictly for laboratory research purposes.
22.5%
Loss in weight using Retatrutide
Reference value drawn from published research on GLP-1 multi-agonist compounds. Provided strictly as scientific context.
600
Clinical study based on 600-calorie reduction in daily intake
Participants consumed fewer calories per day without being instructed to diet – driven by decreased appetite and satiety signaling. Provided strictly as scientific context.
28%
Reported increased energy levels in trials
Reported value in published research relating to GLP-1 multi-agonist compounds. Provided strictly as a scientific reference point.
18.3 KG
Average weight loss during clinical trial period of 48 weeks on high-dose Retatrutide.
Example data point referenced in peer-reviewed studies for GLP-1 multi-agonists.
Alluvi does not promote or imply medical use of its products.
Dedicated to Smarter, Safer Care
At Glicix, we design modern injection pens and accessories that make daily treatment simpler, safer, and more comfortable.
Our products combine precision engineering with patient-centered design, ensuring accuracy, reliability, and ease of use.
With a commitment to quality and innovation, Glicix is redefining how people experience diabetes and GLP-1 therapy — one injection at a time.
